Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:47:04.576Z.
Calculation as of: 2026-10-06T15:47:04.576Z.
Quote observation: 2026-10-06T15:45:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 88e906b5462319013e69f4ee379284aaffb96e00f9acc248208650345dd3e90c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$6.67B
EV/EBITDA Ratio
16.75x
TTM Avg
15.74x
3Y Avg
18.78x
5Y Avg
18.87x
Market Cap
$6.59B
EV/EBITDA Ratio
N/A
TTM Avg
64.66x
3Y Avg
316.14x
5Y Avg
316.14x
Market Cap
$6.56B
EV/EBITDA Ratio
15.43x
TTM Avg
12.72x
3Y Avg
11.11x
5Y Avg
13.30x
Market Cap
$6.51B
EV/EBITDA Ratio
17.00x
TTM Avg
14.43x
3Y Avg
16.48x
5Y Avg
56.22x
Market Cap
$7.39B
EV/EBITDA Ratio
2.23x
TTM Avg
2.95x
3Y Avg
2.95x
5Y Avg
195.03x
Market Cap
$6.02B
EV/EBITDA Ratio
45.55x
TTM Avg
617.82x
3Y Avg
545.60x
5Y Avg
321.06x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.74B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.67B | 16.75x | 15.74x | 18.78x | 18.87x |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.59B | N/A | 64.66x | 316.14x | 316.14x |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.56B | 15.43x | 12.72x | 11.11x | 13.30x |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 17.00x | 14.43x | 16.48x | 56.22x |
| Alkermes plc (ALKS)vs › | $7.14B | 45.85x | 25.66x | 15.19x | 371.09x |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.39B | 2.23x | 2.95x | 2.95x | 195.03x |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.02B | 45.55x | 617.82x | 545.60x | 321.06x |
| GRAIL Inc. (GRAL)vs › | $6.00B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.95B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
